CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Iambic snags $150M IPO for AI-driven cancer pipeline

IPO/OfferingPositive
AI Analysis

Summary

Iambic Therapeutics, a Nvidia-backed cancer-focused biotech, completed a $150 million IPO by pricing 9.38 million shares at $16 each and will begin trading on October 16, 2026.

Importance:7/10
Sentiment:
0.70
IPOCancerAI-drivenNvidia-backed
Related Companies

Read the original article

Published by Endpoints News on October 15, 2026 8:01 AM

Read Original